NH TherAguix announcesthe publication of promising preclinical results of AGuIX® in combination with targeted radioligand therapies (TRT) in the Journal of Nuclear Medicine (October, 2023).
Archives News 2023
NH TherAguix and Jean PERRIN Cancer Centre in Clermont-Ferrand announcement
NH TherAguix and Jean PERRIN Cancer Centre in Clermont-Ferrand
announce the completion of phase I recruitment and the entry into Phase II for the Nano-GBM phase I/II trial in glioblastoma with the two first patients included.
NH TherAguix appoints Vincent Carrère as Chief Executive Officer
NH TherAguix announced the appointment of Vincent Carrère as Chief Executive Officer (CEO).
NH TherAguix announces communications to be presented at the AAPM meeting by Harvard Medical School collaborators
NH TherAguix is happy to announce that 4 communications related to AGuIX will be provided during the American Association for Physicists in Medicine annual meeting in Houston, Texas, USA by our US collaborators